ExCEEd Orphan announces signature of an exclusive Distribution Agreement with Advicenne for marketing and distribution of Sibnayal® in Central and Eastern Europe

ExCEEd Orphan Distribution d.o.o., a Croatia based fully-owned subsidiary of ExCEEd Orphan s.r.o., a company providing full business solutions for the treatment of rare diseases, signed an exclusive Distribution Agreement with Advicenne, the specialty pharmaceutical company targeting patient needs in rare renal diseases, for the distribution and marketing of Sibnayal® in Central and Eastern European (CEE) countries.

Under the terms of the agreement, ExCEEd Orphan will receive the exclusive rights to distribute and market Sibnayal® for the treatment of distal renal tubular acidosis (dRTA) in the CEE countries including Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czechia, Hungary, Kosovo, Montenegro, North Macedonia, Poland, Romania, Serbia, Slovakia, and Slovenia. Sibnayal® received marketing authorisation in the European Union in May 2021 as the first and only label-approved drug for the treatment of Distal Renal Tubular Acidosis (dRTA) in adults, adolescents, and children aged one year and older.

Jiri Hermanek, Chief Executive Officer and Founding Partner of ExCEEd Orphan, commented:
“I personally, and all my colleagues are very pleased to announce this collaboration to make Sibnayal® available to patients suffering from dRTA across Central and Eastern European countries. This unique medicine is the only treatment alternative approved by EMA for treatment of dRTA and as such brings hope to all patients and their relatives. Sibnayal® represents an important addition to continuously growing portfolio of rare disease medications marketed and distributed by ExCEEd Orphan. We are fully committed to bring this unique medication to all patients in needs in all respective countries of CEE region.”

Didier Laurens, Chief Executive Officer of Advicenne, commented:
“We are delighted to have signed collaboration agreements with ExCEEd Orphan for Central & Eastern Europe. This agreement will make Sibnayal™ available to about 20% of the 30,000 European dRTA patients and we are pleased and honored to make this treatment available as quickly as possible. We are looking forward to working with ExCEEd Orphan who have a strong track record of launching orphan medicines within this region.”

About ExCEEd Orphan
ExCEEd Orphan was founded in 2018 by five rare disease experts from multiple Central and Eastern European (CEE) countries. The Company is focusing on innovative treatments for rare diseases and has extensive experience in launching innovative medicines in this field. The portfolio of ExCEEd Orphan includes products in therapeutic areas like haematology, neurology, immunology, and metabolic diseases.

For further information about ExCEEd Orphan, please visit www.exceedorphan.com

Get in touch

With real experts in CEE region.

Send us an e-mail